

## Human Leuprolide - Purified

<b>Catalog No.:</b>	PA1191X
<b>Quantity:</b>	25 mg
<b>Concentration:</b>	1.0 mg/ml
<b>Species:</b>	Human
<b>Source:</b>	Synthetic
<b>Format:</b>	<b>State:</b> Sterile Filtered White lyophilized (freeze-dried) powder. <b>Purity:</b> >98% Greater than 98.0% as determined by: (a) Analysis by RP-HPLC, (b) Mass Spectral Analysis {MALDI-TOF exhibits correct Mw}. <b>Buffer System:</b> Lyophilized from a concentrated solution in water containing no additives. <b>Reconstitution:</b> It is recommended to reconstitute the lyophilized Leuprolide in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
<b>Description:</b>	Synthetic Human Leuprolide is a single, non-glycosylated, polypeptide chain containing 9 amino acids and having a molecular mass of. The b chain has an N-glycosilation site and its structure and glycosilation pattern are very similar to that of pituitary LHRH. <b>AA Sequence:</b> Glu-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH <sub>2</sub> . <b>Molecular weight:</b> 1 kDa 1209 Dalton
<b>Storage:</b>	Lyophilized Leuprolide although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Leuprolide should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.
<b>General Readings:</b>	<ol style="list-style-type: none"><li>1. Chalmers LJ, Casas L, New MI, Blackett PR. Prolongation of growth by treatment of 11-hydroxylase deficiency with depot-leuprolide, growth hormone, and hydrocortisone. J Pediatr Endocrinol Metab. 2006 Oct;19(10):1251-5. PubMed PMID: 17172087.</li><li>2. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8. Eur Urol 2007 Apr;51(4):1146</li><li>3. Mericq G MV, Youlton R R, Willshaw Z ME. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty]. Rev Med Chil. 2006 Jul;134(7):821-6. Epub 2006 Aug 29. PubMed PMID: 17130963.</li><li>4. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. Hum Reprod. 2006 Nov;21(11):2830-7. Epub 2006 Sep 11. PubMed PMID: 16966348.</li><li>5. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug</li></ol>

delivery systems. J Control Release 2006 Oct 10;115(2):158-67  
 6. Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm. 2007 Jan 2;328(1):42-8. Epub 2006 Aug 1. PubMed PMID: 16959451.

**Pictures:**

Precursor- Protein structure and amino acid sequence

